Karp Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Karp Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-78	Closed	-$5K	–	383
2015 Q2	$5K	Buy	+78	New	+$4.81K	﹤0.01%	327

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Karp Capital Management's TEVA Position: Q3 2015 in Review

Karp Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2015, closing a stake of 78 shares — an estimated $5K sold.

Karp Capital Management first reported a position in TEVA in Q2 2015 and held it in 1 quarter. The position peaked at $5K in Q2 2015. 824 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

Karp Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2015 after selling out during the quarter.
Karp Capital Management sold 78 Teva Pharmaceutical Industries Limited shares in Q3 2015, an estimated $5K.
Karp Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2015 and held it in 1 quarter.
Karp Capital Management's Teva Pharmaceutical Industries Limited position peaked at $5K in Q2 2015.
824 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2015.

Based on Karp Capital Management's 13F filing for Q3 2015, filed 3 Nov 2015.